InvestorsHub Logo
Followers 0
Posts 1586
Boards Moderated 1
Alias Born 06/25/2019

Re: None

Friday, 07/17/2020 4:53:32 PM

Friday, July 17, 2020 4:53:32 PM

Post# of 6773
Forbes tackles the bull case for cannabis:

https://www.forbes.com/sites/kriskrane/2020/07/15/us-cannabis-stocks-a-good-investment-in-a-bad-economy/#617480bd1238

The past year has been a tough one for publicly traded cannabis companies, particularly multi-state operators in the United States, many of whom have seen their valuations drop to a quarter of their early 2019 highs. This decline in value coupled with the current Covid-19 virus-fueled economic downturn has many investors sitting on the sidelines. But a host of factors are brewing that could cause a powerful tailwind for the U.S. cannabis industry.

Many U.S. operators, particularly those with a strong focus on operating fundamentals, have already started to see their valuations rebound off the lows from late 2019 and early 2020. But these companies should still have lots of room to grow. In fact, a strong argument can be made that many American cannabis stocks are attractively valued compared to their current and anticipated long-term growth rates.

American cannabis company valuations also continue to lag their peers in Canada, despite what’s demonstrably better recent operational and financial performance and clear sight lines in larger addressable markets. Canada has already legalized cannabis nationwide, and while implementation has been slow and rocky, it is no longer in its initial phases. In a country of only 37 million people, Canadian cannabis companies like Canopy Growth and Aurora must rely on nascent international markets to substantially grow their revenue, while in the U.S., only 11 of 50 states have legalized for adult use and cannabis remains a Schedule I controlled substance at the federal level, leaving lots of room for growth and expansion at home in a country with nearly ten times Canada’s population.

____________________________________

I'd say everything above is true of HLIX.

I'd say that does not apply to KERN, our competitor. Since they are a SPAC and down today, with lots and lots of fall to go. SPAC's are exceptions to the rule. They get catipulted out of orbit with no wings, and come right back down to earth.

Next year: HLIX vs. KERN -- 365 days from now. Will be interesting. Plus, they have Alan's, the confused cannabis canalyst, recent endorsement which "isn't and endorsement."

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.